Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

Figure 2

Changes in serum tumor marker levels during the study in case 11 (A: CEA, B: CA19-9). Levels of CEA stayed within the normal range (0~5.9 ng/ml) until the 4th vaccination, and increased thereafter (A). Levels of CA19-9 stayed within the normal range (0~37 U/ml) throughout the study (B). Arrows indicate the times of vaccination.

Back to article page